Corcept Therapeutics | CORT - Current Liabilities


Corcept Therapeutics reported $153.8M in Current Liabilities for its fiscal quarter ending in June of 2026.





Current Liabilities Change Date
Acadia Pharmaceuticals USD 361.44M 55.91M Jun/2026
Alaunos Therapeutics USD 595K 218K Mar/2026
ANI Pharmaceuticals USD 283.65M 44.14M Jun/2026
Ardelyx USD 109.57M 20.96M Mar/2026
Aurora Cannabis CAD 66.93M 79M Mar/2026
BioMarin Pharmaceutical USD 1.66B 870.84M Jun/2026
Bristol-Myers Squibb USD 18.66B 499M Jun/2026
Canopy Growth CAD 158.44M 60.15M Mar/2026
Corcept Therapeutics USD 153.8M 4.62M Jun/2026
Eli Lilly USD 47.74B 11.11B Jun/2026
J&J USD 54.9B 2.82B Jun/2026
Knight Therapeutics CAD 165.26M 12.58M Dec/2025
Lexicon Pharmaceuticals USD 9.9M 10.97M Mar/2026
Merck USD 27.73B 786M Jun/2026
Nektar Therapeutics USD 57.71M 4.17M Mar/2026
Novartis USD 31.75B 374M Jun/2026
Novartis USD 31.37B 4.1B Mar/2026
Omeros USD 85.5M 2.28M Jun/2025
Pacira USD 122.01M 13.22M Jun/2026
Pfizer USD 32.65B 1.7B Jun/2026
Supernus Pharmaceuticals USD 347.38M 26.55M Jun/2026
TG Therapeutics USD 268.49M 81.38M Jun/2026